1
|
Schwartz RA: The keratoacanthoma: A
review. J Surg Oncol. 12:305–317. 1979. View Article : Google Scholar : PubMed/NCBI
|
2
|
Misago N, Inoue T, Koba S and Narisawa Y:
Keratoacanthoma and other types of squamous cell carcinoma with
crateriform architecture: Classification and identification. J
Dermatol. 40:443–452. 2013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Hodak E, Jones RE and Ackerman AB:
Solitary keratoacanthoma is a squamous-cell carcinoma: Three
examples with metastases. Am J Dermatopathol. 15:332–342;
discussion 343–352. 1993. View Article : Google Scholar : PubMed/NCBI
|
4
|
Weedon DD, Malo J, Brooks D and Williamson
R: Squamous cell carcinoma arising in keratoacanthoma: A neglected
phenomenon in the elderly. Am J Dermatopathol. 32:423–426. 2010.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Kossard S, Tan KB and Choy C:
Keratoacanthoma and infundibulocystic squamous cell carcinoma. Am J
Dermatopathol. 30:127–134. 2008. View Article : Google Scholar : PubMed/NCBI
|
6
|
Misago N, Inoue T, Toda S and Narisawa Y:
Infundibular (follicular) and infundibulocystic squamous cell
carcinoma: A clinicopathological and immunohistochemical study. Am
J Dermatopathol. 33:687–694. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Müeller-Pillasch F, Lacher U, Wallrapp C,
Micha A, Zimmerhackl F, Hameister H, Varga G, Friess H, Büchler M,
Beger HG, et al: Cloning of a gene highly overexpressed in cancer
coding for a novel KH-domain containing protein. Oncogene.
14:2729–2733. 1997. View Article : Google Scholar : PubMed/NCBI
|
8
|
Nielsen J, Christiansen J, Lykke-Andersen
J, Johnsen AH, Wewer UM and Nielsen FC: A family of insulin-like
growth factor II mRNA-binding proteins represses translation in
late development. Mol Cell Biol. 19:1262–1270. 1999. View Article : Google Scholar : PubMed/NCBI
|
9
|
Simon R, Bourne PA, Yang Q, Spaulding BO,
di Sant'Agnese PA, Wang HL and Xu H: Extrapulmonary small cell
carcinomas express K homology domain containing protein
overexpressed in cancer, but carcinoid tumors do not. Hum Pathol.
38:1178–1183. 2007. View Article : Google Scholar : PubMed/NCBI
|
10
|
Hammer NA, Hansen T, Byskov AG, Rajpert-De
Meyts E, Grøndahl ML, Bredkjaer HE, Wewer UM, Christiansen J and
Nielsen FC: Expression of IGF-II mRNA-binding proteins (IMPs) in
gonads and testicular cancer. Reproduction. 130:203–212. 2005.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Pryor JG, Simon RA, Bourne PA, Spaulding
BO, Scott GA and Xu H: Merkel cell carcinoma expresses K homology
domain-containing protein overexpressed in cancer similar to other
high-grade neuroendocrine carcinomas. Hum Pathol. 40:238–243. 2009.
View Article : Google Scholar
|
12
|
Righi A, Zhang S, Jin L, Scheithauer BW,
Kovacs K, Kovacs G, Goth MI, Korbonits M and Lloyd RV: Analysis of
IMP3 expression in normal and neoplastic human pituitary tissues.
Endocr Pathol. 21:25–31. 2010. View Article : Google Scholar
|
13
|
King RL, Pasha T, Roullet MR, Zhang PJ and
Bagg A: IMP-3 is differentially expressed in normal and neoplastic
lymphoid tissue. Hum Pathol. 40:1699–1705. 2009. View Article : Google Scholar : PubMed/NCBI
|
14
|
Liao B, Hu Y, Herrick DJ and Brewer G: The
RNA-binding protein IMP-3 is a translational activator of
insulin-like growth factor II leader-3 mRNA during proliferation of
human K562 leukemia cells. J Biol Chem. 280:18517–18524. 2005.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Clauditz TS, Wang CJ, Gontarewicz A,
Blessmann M, Tennstedt P, Borgmann K, Tribius S, Sauter G, Dalchow
C, Knecht R, et al: Expression of insulin-like growth factor II
mRNA-binding protein 3 in squamous cell carcinomas of the head and
neck. J Oral Pathol Med. 42:125–132. 2013. View Article : Google Scholar
|
16
|
Wang T, Fan L, Watanabe Y, McNeill PD,
Moulton GG, Bangur C, Fanger GR, Okada M, Inoue Y, Persing DH, et
al: L523S, an RNA-binding protein as a potential therapeutic target
for lung cancer. Br J Cancer. 88:887–894. 2003. View Article : Google Scholar : PubMed/NCBI
|
17
|
Pryor JG, Bourne PA, Yang Q, Spaulding BO,
Scott GA and Xu H: IMP-3 is a novel progression marker in malignant
melanoma. Mod Pathol. 21:431–437. 2008. View Article : Google Scholar : PubMed/NCBI
|
18
|
Sheen YS, Liao YH, Lin MH, Chu CY, Ho BY,
Hsieh MC, Chen PC, Cha ST, Jeng YM, Chang CC, et al: IMP-3 promotes
migration and invasion of melanoma cells by modulating the
expression of HMGA2 and predicts poor prognosis in melanoma. J
Invest Dermatol. 135:1065–1073. 2015. View Article : Google Scholar
|
19
|
Yu L, Xu H, Wasco MJ, Bourne PA and Ma L:
IMP-3 expression in melanocytic lesions. J Cutan Pathol.
37:316–322. 2010. View Article : Google Scholar
|
20
|
Mentrikoski MJ, Ma L, Pryor JG, McMahon
LA, Yang Q, Spaulding BO, Scott GA, Wang HL and Xu H: Diagnostic
utility of IMP3 in segregating metastatic melanoma from benign nevi
in lymph nodes. Mod Pathol. 22:1582–1587. 2009. View Article : Google Scholar : PubMed/NCBI
|
21
|
Takata A, Takiguchi S, Okada K, Takahashi
T, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Mori M and Doki Y:
Expression of insulin-like growth factor-II mRNA-binding protein-3
as a marker for predicting clinical outcome in patients with
esophageal squamous cell carcinoma. Oncol Lett. 8:2027–2031.
2014.PubMed/NCBI
|
22
|
Zhang J, Ou Y, Ma Y, Zheng L, Zhang X, Xia
R, Kong F, Shen Y, Wang S and Lin L: Clinical implications of
insulin-like growth factor II mRNA-binding protein 3 expression in
non-small cell lung carcinoma. Oncol Lett. 9:1927–1933.
2015.PubMed/NCBI
|
23
|
Pasiliao CC, Chang CW, Sutherland BW,
Valdez SM, Schaeffer D, Yapp DT and Ng SS: The involvement of
insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic
cancer cell migration, invasion, and adhesion. BMC Cancer.
15:2662015. View Article : Google Scholar : PubMed/NCBI
|
24
|
Soddu S, Di Felice E, Cabras S,
Castellanos ME, Atzori L, Faa G and Pilloni L: IMP-3 expression in
keratoacanthomas and squamous cell carcinomas of the skin: an
immunohistochemical study. Eur J Histochem. 57:e62013. View Article : Google Scholar : PubMed/NCBI
|
25
|
Kondo S, Hozumi Y and Aso K: Autocrine
secretion of an EGF-like substance by a cell line (HSC-1) derived
from a human skin squamous cell carcinoma. J Dermatol Sci.
2:161–165. 1991. View Article : Google Scholar : PubMed/NCBI
|
26
|
Hozumi Y, Kondo S, Shimoura T and Aso K:
Human squamous cell carcinoma from skin: Establishment and
characterization of a new cell line (HSC-5). J Dermatol.
17:143–148. 1990. View Article : Google Scholar : PubMed/NCBI
|
27
|
Abdou AG, Maraee AH, El-Sayed EM and
Elnaidany NF: Immunohistochemical expression of ezrin in cutaneous
basal and squamous cell carcinomas. Ann Diagn Pathol. 15:394–401.
2011.PubMed/NCBI
|
28
|
Pei X, Li M, Zhan J, Yu Y, Wei X, Guan L,
Aydin H, Elson P, Zhou M, He H, et al: Enhanced IMP3 expression
activates NF-κB pathway and promotes renal cell carcinoma
progression. PLoS One. 10:e01243382015. View Article : Google Scholar
|
29
|
Su P, Hu J, Zhang H, Li W, Jia M, Zhang X,
Wu X, Cheng H, Xiang L and Zhou G: IMP3 expression is associated
with epithelial-mesenchymal transition in breast cancer. Int J Clin
Exp Pathol. 7:3008–3017. 2014.PubMed/NCBI
|
30
|
Lin CY, Chen ST, Jeng YM, Yeh CC, Chou HY,
Deng YT, Chang CC and Kuo MY: Insulin-like growth factor II
mRNA-binding protein 3 expression promotes tumor formation and
invasion and predicts poor prognosis in oral squamous cell
carcinoma. J Oral Pathol Med. 40:699–705. 2011. View Article : Google Scholar : PubMed/NCBI
|
31
|
Kim KY, Li S, Cha JD, Zhang X and Cha IH:
Significance of molecular markers in survival prediction of oral
squamous cell carcinoma. Head Neck. 34:929–936. 2012. View Article : Google Scholar
|
32
|
Wei Q, Yan J, Fu B, Liu J, Zhong L, Yang Q
and Zhao T: IMP3 expression is associated with poor survival in
cervical squamous cell carcinoma. Hum Pathol. 45:2218–2224. 2014.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Li HG, Han JJ, Huang ZQ, Wang L, Chen WL
and Shen XM: IMP3 is a novel biomarker to predict metastasis and
prognosis of tongue squamous cell carcinoma. J Craniofac Surg.
22:2022–2025. 2011. View Article : Google Scholar : PubMed/NCBI
|
34
|
Schwartz RA: Keratoacanthoma: A
clinico-pathologic enigma. Dermatol Surg. 30:326–333.
2004.PubMed/NCBI
|
35
|
Sánchez Yus E, Simón P, Requena L, Ambrojo
P and de Eusebio E: Solitary keratoacanthoma: A self-healing
proliferation that frequently becomes malignant. Am J
Dermatopathol. 22:305–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
36
|
Weedon D, Malo J, Brooks D and Williamson
R: Keratoacanthoma: Is it really a variant of squamous cell
carcinoma? ANZ J Surg. 80:129–130. 2010. View Article : Google Scholar : PubMed/NCBI
|
37
|
Ni C, Su A, Ra S, Li X, Cochran A and
Binder S: Squamous cell carcinoma arising from keratoacanthoma: An
evaluation by RT-PCR. Am J Dermatopathol. Jun 2–2015.Epub ahead of
print. View Article : Google Scholar : PubMed/NCBI
|
38
|
Hu S, Wu X, Zhou B, Xu Z, Qin J, Lu H, Lv
L, Gao Y, Deng L, Yin J, et al: IMP3 combined with CD44s, a novel
predictor for prognosis of patients with hepatocellular carcinoma.
J Cancer Res Clin Oncol. 140:883–893. 2014. View Article : Google Scholar : PubMed/NCBI
|
39
|
Liu K, Kasper M, Bierhaus A, Langer S,
Peterson I, Müller M and Trott KR: Differential expression of CD44s
and CD44v10 proteins and syndecan in normal and irradiated mouse
epidermis. Histochem Cell Biol. 107:159–167. 1997. View Article : Google Scholar : PubMed/NCBI
|
40
|
Bourguignon LY: Matrix
hyaluronan-activated CD44 signaling promotes keratinocyte
activities and improves abnormal epidermal functions. Am J Pathol.
184:1912–1919. 2014. View Article : Google Scholar : PubMed/NCBI
|
41
|
Brown DC and Gatter KC: Ki67 protein: The
immaculate deception? Histopathology. 40:2–11. 2002. View Article : Google Scholar : PubMed/NCBI
|
42
|
Ribeiro D, Narikawa S and Marques ME:
Expression of apoptotic and cell proliferation regulatory proteins
in keratoacanthomas and squamous cell carcinomas of the skin.
Pathol Res Pract. 204:97–104. 2008. View Article : Google Scholar
|
43
|
Scola N, Segert HM, Stücker M, Altmeyer P,
Gambichler T and Kreuter A: Ki-67 may be useful in differentiating
between keratoacanthoma and cutaneous squamous cell carcinoma. Clin
Exp Dermatol. 39:216–218. 2014. View Article : Google Scholar : PubMed/NCBI
|
44
|
Rivera Vargas T, Boudoukha S, Simon A,
Souidi M, Cuvellier S, Pinna G and Polesskaya A:
Post-transcriptional regulation of cyclins D1, D3 and G1 and
proliferation of human cancer cells depend on IMP-3 nuclear
localization. Oncogene. 33:2866–2875. 2014. View Article : Google Scholar
|
45
|
Lin L, Zhang J, Wang Y, Ju W, Ma Y, Li L
and Chen L: Insulin-like growth factor-II mRNA-binding protein 3
predicts a poor prognosis for colorectal adenocarcinoma. Oncol
Lett. 6:740–744. 2013.PubMed/NCBI
|